Pityriasis rubra pilaris‐like eruption following administration of the BNT163b2 (Pfizer–BioNTech) mRNA COVID‐19 vaccine

Hunjan, Manrup K.; Roberts, Connor; Karim, Saad Kazim; Hague, J. S.

doi:10.1111/ced.14878

Cited by 25 publications

(47 citation statements)

References 5 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three of five erythema multiforme cases were associated with the mRNA-1273 vaccine [ 1 , 62 , 63 ]. New onset of prurigo nodularis [ 17 ], radiation recall dermatitis [ 64 ], symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)-like eruption [ 65 ], Stevens-Johnson syndrome/toxic epidermal necrolysis [ 66 , 67 , 68 ], Sweet’s syndrome [ 69 , 70 ], vitiligo [ 71 ], vasculitis [ 50 , 72 , 73 ], livedo racemosa [ 27 ], fixed drug eruption [ 27 ], pityriasis rubra pilaris-like eruption [ 74 ], and facial pustular neutrophilic eruption [ 75 ] have been reported post-vaccination. All SJS and Sweet’s syndrome cases were managed successfully.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Two middle-aged women developed a rosacea-like eruption 4 to 5 days after Ad26.CoV2.S and BNT162b2 vaccination [57]. In some patients, COVID vaccination may induce a new onset of psoriatic disease, presenting as chronic plaque psoriasis [58,59], palmoplantar psoriasis [60], guttate psoriasis [61], generalized pustular psoriasis [62], and even pityriasis rubra pilaris [63].…”

Section: Other Dermatosesmentioning

confidence: 99%

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

Many patients are receiving SARS-CoV-2 vaccinations, which have been associated with a variety of adverse effects. Cutaneous adverse reactions to SARS-CoV-2 vaccinations have been progressively reported, but they have not been reviewed according to their morphological clinical patterns. The objective of this review was to summarize the existing data concerning the cutaneous adverse reactions following SARS-CoV-2 vaccines and group them according to common morphological and pathogenetic patterns. We reviewed the English language literature up to 15 August 2021, using predefined keywords to identify the relevant studies evaluating cutaneous adverse reactions associated with SARS-CoV-2 vaccines. We search for recurrent morphological patterns sharing clinical signs and symptoms and physio-pathological mechanisms. Timing to onset following the first or booster dose of the vaccine, predisposing conditions, therapeutic management, and outcome were also collected. Among the dermatological manifestations associated with SARS-CoV-2 vaccinations, we distinguished: (1) new onset reactions and (2) flares of preexisting dermatoses. The most common were injection site reactions, affecting 30–70% and generally mild or moderate. Small case series or single case reports included filler reactions, exanthemas, vascular lesions, urticaria, eczematous dermatitis, autoimmune bullous reactions, and severe cutaneous adverse reactions. In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported. The cutaneous reactions were generally mild, self-limiting, and resembled common cutaneous drug eruptions and/or COVID-19 skin manifestations.

show abstract

“… 2 Multiple cutaneous adverse events were associated with COVID‐19 and its vaccines, to date, there are four reports of PRP related to COVID‐19 vaccination. 3 , 4 , 5 , 6 Here, we report two cases of PRP after ChAdOx1 (AstraZeneca) vaccine, compare them with other similar cases and highlight a satisfactory response with oral isotretinoin.…”

Section: Figurementioning

confidence: 71%

“…Their age varied from 31 to 82 years, both sexes were affected and different types of PRP have been presented. 3 , 4 , 5 , 6 Four patients presented the onset of adverse reactions in a mean time of 13 days after the first dose, 3 , 4 , 5 one presented flare after the first and second dose 6 and two of them after a medium of 6,5 days after the second dose. 3 Four patients (57.14%) received (AstraZeneca), 4 , 5 one (14.28%) mRNA‐1273 (Moderna) 3 and two (28,58%) BNT16B2b2 (BioNTech/Pfizer).…”

Section: Figurementioning

confidence: 97%

Pityriasis rubra pilaris (type I) following ChAdOx1 COVID‐19 vaccine: A report of two cases with successful treatment with oral isotretinoin

Criado

Ianhez

Rocha³

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Pityriasis rubra pilaris‐like eruption following administration of the BNT163b2 (Pfizer–BioNTech) mRNA COVID‐19 vaccine

Cited by 25 publications

References 5 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Pityriasis rubra pilaris (type I) following ChAdOx1 COVID‐19 vaccine: A report of two cases with successful treatment with oral isotretinoin

Contact Info

Product

Resources

About